Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development
Alzamend Neuro’s bipolar disorder trial was paused and its related statement of work terminated as the company seeks FDA guidance on a revised AL001 development plan.Key Highlights:Original SEC Filing: Alzamend Neuro, Inc. [ ALZN ] - 8-K - Nov. 17, 2026This is an AI-powered summary. It may contain…